GlassScriptPhysician profile
Yiping Fu
NPI 1043205107
$13,391.82
in general payments reported to CMS, 2019-2025
34 companies · $21.97 in 2025
The $21.97 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,441 · 2020: $420 · 2021: $735 · 2022: $1,433 · 2023: $1,068 · 2024: $6,273 · 2025: $21.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,356 · Education: $3,000 · Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,356.04 |
| Education | $3,000.00 |
| Food and Beverage | $1,007.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,050.79 | 2022-2024 | |
| Pinnacle Biologics, INC | $1,993.28 | 2019 | |
| Medical Device Business Services, INC. | $806.51 | 2023 | |
| Ethicon INC. | $708.54 | 2021 | |
| Merck Sharp & Dohme LLC | $355.40 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $350.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.10 | 2019-2024 | Enhertu |
| Amgen INC. | $272.75 | 2019-2020 | |
| Pfizer INC. | $216.53 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.62 | 2019-2024 | Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $168.63 | 2019-2020 | |
| Lilly USA, LLC | $167.68 | 2019-2024 | Verzenio |
| Taiho Oncology, INC. | $95.15 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $73.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $62.55 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $61.20 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $57.55 | 2019 | |
| Celgene Corporation | $55.02 | 2019 | |
| Blueprint Medicines Corporation | $46.99 | 2023-2024 | Ayvakit |
| Astellas Pharma US INC | $45.57 | 2024 | Xtandi |
| Servier Pharmaceuticals LLC | $42.29 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $34.92 | 2019 | |
| Daiichi Sankyo INC. | $29.72 | 2023 | Injectafer |
| Emd Serono, INC. | $27.84 | 2024 | |
| Seagen INC. | $25.34 | 2023 | Padcev |
| Inari Medical, INC. | $20.72 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Coherus Oncology, INC. | $20.34 | 2020 | |
| Janssen Biotech, INC. | $19.31 | 2024 | Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.83 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.90 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $13.65 | 2020 | |
| Exelixis INC. | $11.94 | 2019 | |
| Abbvie INC. | $11.91 | 2019 | |
| Electromed, INC. | $7.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiping Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.